Short-acting β
Asthma
Exacerbations
Prescriptions
Short-acting β2-agonists
Turkey
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
02 Jun 2022
02 Jun 2022
Historique:
received:
17
11
2021
accepted:
28
04
2022
entrez:
2
6
2022
pubmed:
3
6
2022
medline:
7
6
2022
Statut:
epublish
Résumé
Over-reliance on short-acting β This observational, cross-sectional study included patients aged ≥ 12 years with asthma from 24 centres across Turkey. Data on sociodemographics, disease characteristics and asthma treatments were collected using electronic case report forms. Patients were classified by investigator-defined asthma severity (guided by the 2017 Global Initiative for Asthma [GINA]) and practice type (primary/specialist care). The primary objective was to describe SABA prescription patterns in the 12 months prior to the study visit. Overall, 579 patients were included (mean age [standard deviation; SD]: 47.4 [16.1] years; 74.3% female), all of whom were treated by specialists. Most patients had moderate-to-severe asthma (82.7%, GINA steps 3-5), were overweight or obese (70.5%), had high school or university/post-graduate education (51.8%) and reported fully reimbursed healthcare (97.1%). The mean (SD) asthma duration was 12.0 (9.9) years. Asthma was partly controlled/uncontrolled in 56.3% of patients, and 46.5% experienced ≥ 1 severe exacerbation in the preceding 12 months. Overall, 23.9% of patients were prescribed ≥ 3 SABA canisters in the previous 12 months (considered over-prescription); 42.9% received no SABA prescriptions. As few patients had mild asthma, only 5.7% were prescribed SABA monotherapy. Therefore, most patients (61.5%) were prescribed SABA in addition to maintenance therapy, with 42.8% receiving ≥ 3 SABA canisters in the previous 12 months. Inhaled corticosteroids (ICS), ICS + a long-acting β-agonist fixed-dose combination and oral corticosteroids were prescribed to 14.5%, 88.3% and 28.5% of all patients, respectively. Additionally, 10.2% of patients purchased SABA over the counter, of whom 27.1% purchased ≥ 3 canisters in the preceding 12 months. Despite all patients being treated by specialists and most receiving fully reimbursed healthcare, nearly a quarter of patients received prescriptions for ≥ 3 SABA canisters in the previous 12 months. This highlights a public health concern and emphasizes the need to align clinical practices with the latest evidence-based recommendations.
Sections du résumé
BACKGROUND
BACKGROUND
Over-reliance on short-acting β
METHODS
METHODS
This observational, cross-sectional study included patients aged ≥ 12 years with asthma from 24 centres across Turkey. Data on sociodemographics, disease characteristics and asthma treatments were collected using electronic case report forms. Patients were classified by investigator-defined asthma severity (guided by the 2017 Global Initiative for Asthma [GINA]) and practice type (primary/specialist care). The primary objective was to describe SABA prescription patterns in the 12 months prior to the study visit.
RESULTS
RESULTS
Overall, 579 patients were included (mean age [standard deviation; SD]: 47.4 [16.1] years; 74.3% female), all of whom were treated by specialists. Most patients had moderate-to-severe asthma (82.7%, GINA steps 3-5), were overweight or obese (70.5%), had high school or university/post-graduate education (51.8%) and reported fully reimbursed healthcare (97.1%). The mean (SD) asthma duration was 12.0 (9.9) years. Asthma was partly controlled/uncontrolled in 56.3% of patients, and 46.5% experienced ≥ 1 severe exacerbation in the preceding 12 months. Overall, 23.9% of patients were prescribed ≥ 3 SABA canisters in the previous 12 months (considered over-prescription); 42.9% received no SABA prescriptions. As few patients had mild asthma, only 5.7% were prescribed SABA monotherapy. Therefore, most patients (61.5%) were prescribed SABA in addition to maintenance therapy, with 42.8% receiving ≥ 3 SABA canisters in the previous 12 months. Inhaled corticosteroids (ICS), ICS + a long-acting β-agonist fixed-dose combination and oral corticosteroids were prescribed to 14.5%, 88.3% and 28.5% of all patients, respectively. Additionally, 10.2% of patients purchased SABA over the counter, of whom 27.1% purchased ≥ 3 canisters in the preceding 12 months.
CONCLUSIONS
CONCLUSIONS
Despite all patients being treated by specialists and most receiving fully reimbursed healthcare, nearly a quarter of patients received prescriptions for ≥ 3 SABA canisters in the previous 12 months. This highlights a public health concern and emphasizes the need to align clinical practices with the latest evidence-based recommendations.
Identifiants
pubmed: 35655251
doi: 10.1186/s12890-022-02008-9
pii: 10.1186/s12890-022-02008-9
pmc: PMC9161536
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Adrenergic beta-2 Receptor Agonists
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
216Investigateurs
Deniz Kızılırmak
(D)
Nejat Altıntaş
(N)
İsmet Bulut
(İ)
Tülin Çağatay
(T)
Bilun Gemicioğlu
(B)
Özgür İnce
(Ö)
Kıvılcım Oğuzülgen
(K)
Füsun Kalpaklıoğlu
(F)
Ayşe Baççıoğlu
(A)
Funda Aksu
(F)
Murat Altuntaş
(M)
Ferda Öner Erkekol
(FÖ)
Gül Karakaya
(G)
Ali Fuat Kalyoncu
(AF)
Ebru Damadoğlu
(E)
İsmail Hanta
(İ)
Ersoy Altunok
(E)
Adviye Özer
(A)
Demet Polat Yuluğ
(DP)
Gazi Gülbaş
(G)
Mecit Süerdem
(M)
Burcu Yormaz
(B)
Emel Ceylan
(E)
Duygu Erge
(D)
Aykut Çilli
(A)
Berat Celil Doğan
(BC)
Fuat Erel
(F)
Can Sevinç
(C)
Ceyda Anar
(C)
Gülseren Pekbak
(G)
Müge Erbay
(M)
Informations de copyright
© 2022. The Author(s).
Références
J Clin Invest. 2020 Feb 3;130(2):565-574
pubmed: 32011317
J Asthma. 2019 May;56(5):553-561
pubmed: 29714602
J Thorac Dis. 2018 Mar;10(3):2052-2058
pubmed: 29707363
Curr Allergy Asthma Rep. 2019 Sep 10;19(10):49
pubmed: 31506820
Clin Respir J. 2017 Mar;11(2):210-223
pubmed: 26073091
Cochrane Database Syst Rev. 2018 Jun 25;6:CD002741
pubmed: 29938789
Pharm World Sci. 2007 Jun;29(3):199-204
pubmed: 17242857
Value Health Reg Issues. 2017 Sep;13:31-38
pubmed: 29073985
J Allergy Clin Immunol Pract. 2018 May - Jun;6(3):886-894.e4
pubmed: 29408439
Pharmacoepidemiol Drug Saf. 2021 Sep;30(9):1242-1249
pubmed: 34155708
Am J Rhinol Allergy. 2013 Nov-Dec;27(6):482-9
pubmed: 24274224
Respir Med. 2017 Oct;131:135-140
pubmed: 28947020
BMC Pulm Med. 2006 Jun 13;6:13
pubmed: 16772035
J Asthma Allergy. 2019 Sep 23;12:297-307
pubmed: 31576150
Ann Allergy Asthma Immunol. 2012 Dec;109(6):403-7
pubmed: 23176877
Am J Respir Crit Care Med. 2000 May;161(5):1459-64
pubmed: 10806139
Thorax. 2008 Jan;63(1):14-20
pubmed: 18156567
Eur Respir J. 2017 Sep 9;50(3):
pubmed: 28889114
Respir Med. 2006 Oct;100(10):1850-4
pubmed: 16564685
Eur Respir J. 2022 May 5;59(5):
pubmed: 34561293
Expert Rev Respir Med. 2016 Sep;10(9):943-56
pubmed: 27485393
Eur Ann Allergy Clin Immunol. 2021 May;53(3):128-137
pubmed: 32372589
Allergy Asthma Clin Immunol. 2020 May 27;16:39
pubmed: 32508939
J Asthma. 2010 Jun;47(5):557-62
pubmed: 20560829
Clin Microbiol Infect. 2019 Jun;25(6):651-653
pubmed: 30844434
Eur Respir J. 2020 Feb 12;55(2):
pubmed: 31806716
Med J Aust. 1989 Apr 17;150(8):445-9
pubmed: 2716682
Respir Med. 2012 Feb;106(2):223-9
pubmed: 22040532
BMJ Open. 2017 Sep 25;7(9):e016688
pubmed: 28947448
Sociol Health Illn. 2021 Jul;43(6):1372-1387
pubmed: 34086996
BMC Pulm Med. 2018 May 11;18(1):68
pubmed: 29751756
J Asthma. 2014 Nov;51(9):982-8
pubmed: 24856971
BMJ. 1993 Jun 5;306(6891):1514-8
pubmed: 8518681
Asthma Res Pract. 2017 Jan 6;3:1
pubmed: 28078100
Adv Ther. 2020 Mar;37(3):1124-1135
pubmed: 31981105
Adv Ther. 2020 Oct;37(10):4190-4208
pubmed: 32720299
Turk Thorac J. 2020 Jul;21(4):248-254
pubmed: 32687785
Eur Respir J. 2020 Apr 16;55(4):
pubmed: 31949111
J Asthma Allergy. 2013 Jul 01;6:93-101
pubmed: 23843695
Am J Respir Crit Care Med. 2009 Jul 1;180(1):59-99
pubmed: 19535666
Eur Respir J. 2021 Jul 1;58(1):
pubmed: 33419889
J Clin Transl Sci. 2019 Dec 26;4(1):61-68
pubmed: 32257412
Cochrane Database Syst Rev. 2012 May 16;(5):CD002314
pubmed: 22592685
J Allergy Clin Immunol. 2008 Sep;122(3):507-11.e6
pubmed: 18774387